Role of Vitamin D in Chronic Kidney Disease

Seminars in Nephrology

Volumn 29, Issue 2, 2009, Pages 113-121

  Patel, Tejas V ^a   Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

calcitriol; CKD; dialysis; FGF 23; hyperparathyroidism; klotho; paricalcitol; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; ATORVASTATIN; CALCITRIOL; COLECALCIFEROL; DOXERCALCIFEROL; ENALAPRIL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PARATHYROID HORMONE; PARICALCITOL; VITAMIN D;

ALBUMINURIA; ARTICLE; BLOOD VESSEL CALCIFICATION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG FATALITY; DRUG MEGADOSE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MORTALITY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCITRIOL; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; VITAMIN D;

EID: 64049094752     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.01.004     Document Type: Article

References (87)

1. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
2. USRDS morbidity and mortality 2007 data. [cited 2008 August 15]. Available from: http://www.usrds.org/2007/pdf/06_hosp_morte_07.pdf.
3. Zoccali C., Tripepi G., and Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 25 (2005) 358-362
4. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (2003) S1-S201
5. Martin K.J., and Gonzalez E.A. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol 24 (2004) 456-459
6. Wolf G. The discovery of vitamin D: the contribution of Adolf Windaus. J Nutr 134 (2004) 1299-1302
7. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., and Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74 (1984) 2136-2143
8. Brunette M.G., Chan M., Ferriere C., and Roberts K.D. Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature 276 (1978) 287-289
9. Christakos S., Dhawan P., Liu Y., Peng X., and Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem 88 (2003) 695-705
10. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem 389 (2008) 233-241
11. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 45-51
12. Sitara D., Razzaque M.S., Hesse M., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23 (2004) 421-432
13. Liu S., Tang W., Zhou J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17 (2006) 1305-1315
14. Krajisnik T., Bjorklund P., Marsell R., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195 (2007) 125-131
15. Liu S., Gupta A., and Quarles L.D. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16 (2007) 329-335
16. Fliser D., Kollerits B., Neyer U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18 (2007) 2600-2608
17. Gutierrez O.M., Mannstadt M., Isakova T., et al. fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008) 584-592
18. Memon F., El-Abbadi M., Nakatani T., Taguchi T., Lanske B., and Razzaque M.S. Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism?. Kidney Int 74 (2008) 566-570
19. Torres P.U., Prie D., Molina-Bletry V., Beck L., Silve C., and Friedlander G. Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 71 (2007) 730-737
20. Shoji T., Shinohara K., Kimoto E., et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 (2004) 179-184
21. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70 (2006) 1858-1865
22. Melamed M.L., Eustace J.A., Plantinga L., et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70 (2006) 351-357
23. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., and Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 (2003) 446-456
24. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16 (2005) 1115-1125
25. Palmer S.C., McGregor D.O., Macaskill P., Craig J.C., Elder G.J., and Strippoli G.F. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147 (2007) 840-853
26. Thadhani R. Activated vitamin D sterols in kidney disease. Lancet 371 (2008) 542-544
27. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., and Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168 (2008) 397-403
28. Shoben A.B., Rudser K.D., de Boer I.H., Young B., and Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19 (2008) 1613-1619
29. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
30. Milliner D.S., Zinsmeister A.R., Lieberman E., and Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38 (1990) 931-936
31. Goldsmith D.J., Covic A., Sambrook P.A., and Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 77 (1997) 37-43
32. Berlyne G.M., and Mallick N.P. Arterial calcification after vitamin D. Lancet 1 (1969) 416
33. Kingma Jr. J.G., and Roy P.E. Ultrastructural study of hypervitaminosis D induced arterial calcification in Wistar rats. Artery 16 (1988) 51-61
34. Watson K.E., Abrolat M.L., Malone L.L., et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96 (1997) 1755-1760
35. Andress D.L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69 (2006) 33-43
36. Drissi H., Pouliot A., Koolloos C., et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 274 (2002) 323-333
37. Mathew S., Lund R.J., Chaudhary L.R., Geurs T., and Hruska K.A. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19 (2008) 1509-1519
38. Cardus A., Panizo S., Parisi E., Fernandez E., and Valdivielso J.M. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22 (2007) 860-866
39. Noonan W., Koch K., Nakane M., et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 23 (2008) 3824-3830
40. Fine A., and Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61 (2002) 2210-2217
41. Nigwekar S.U., Wolf M., Sterns R.H., and Hix J.K. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 3 (2008) 1139-1143
42. Foley R.N. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 16 (2003) 111-117
43. Pilz S., Marz W., Wellnitz B., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93 (2008) 3927-3935
44. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288 (2005) E125-E132
45. Bodyak N., Ayus J.C., Achinger S., et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104 (2007) 16810-16815
46. Thadhani R. Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter. Kidney Int 74 (2008) 141-143
47. Zhou C., Lu F., Cao K., Xu D., Goltzman D., and Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74 (2008) 170-179
48. Becker L., Koleganova N., Piecha G., Geldyyev A., Noronha I.L., Waldherr R., et al. Effect of paricalcitol and calcitriol on cardiovascular disease in uninephrectomized ApoE knockout mice. Paper presented at: American Society of Nephrology Annual Meeting; (2007) Nov 2-5; San Francisco, CA
49. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., and Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83 (2006) 754-759
50. Park C.W., Oh Y.S., Shin Y.S., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33 (1999) 73-81
51. Brumbaugh P.F., and Haussler M.R. Specific binding of 1alpha,25-dihydroxycholecalciferol to nuclear components of chick intestine. J Biol Chem 250 (1975) 1588-1594
52. Levin A., Gutierrez O., Andress D.L., and Wolf M. Deficiencies of 25D, 1,25D and inflammation are associated with albuminuria. Paper presented at: American Society of Nephrology Annual Meeting; (2007) Nov 2-5; San Francisco, CA
53. Agarwal R., Acharya M., Tian J., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68 (2005) 2823-2828
54. Alborzi P., Patel N.A., Peterson C., et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52 (2008) 249-255
55. Panichi V., Migliori M., Taccola D., et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 60 (2001) 87-95
56. Kuhlmann A., Haas C.S., Gross M.L., et al. 1,25-dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286 (2004) F526-F533
57. Makibayashi K., Tatematsu M., Hirata M., et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158 (2001) 1733-1741
58. Tan X., Li Y., and Liu Y. Therapeutic role and potential mechanisms of active vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol 103 (2007) 491-496
59. [cited 2008 June 9]. Available from: http://nobelprize.org/nobel_prizes/medicine/laureates/1929/.
60. Vanholder R., and Van Biesen W. Incidence of infectious morbidity and mortality in dialysis patients. Blood Purif 20 (2002) 477-480
61. Bikle D.D. Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens 17 (2008) 348-352
62. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006) 1770-1773
63. Mandayam S., and Shahinian V.B. Are chronic dialysis patients at increased risk for cancer?. J Nephrol 21 (2008) 166-174
64. Beer T.M., and Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 3 (2004) 373-381
65. Guyton K.Z., Kensler T.W., and Posner G.H. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev 61 (2003) 227-238
66. Asakura H., Aoshima K., Suga Y., et al. Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models. Thromb Haemost 85 (2001) 287-290
67. Aihara K., Azuma H., Akaike M., et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 279 (2004) 35798-35802
68. Dusso A.S., Sato T., Arcidiacono M.V., et al. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl (2006) S8-1
69. Arcidiacono M.V., Sato T., Alvarez-Hernandez D., et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 19 (2008) 310-320
70. Tokumoto M., Alvarez-Hernandez D., Archidiacono M.V., Andia J.C., Skatopolsky E., and Dusso A. Contribution of reduced parathyroid vitamin D receptor (VDR) to the switch from diffuse to nodular growth in secondary hyperparathyroidism. Paper presented at: American Society of Nephrology Annual Meeting; (2007) Nov 2-5; San Francisco, CA
71. Blair D., Byham-Gray L., Lewis E., and McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18 (2008) 375-382
72. Mehrotra R., Kermah D., Budoff M., et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3 (2008) 1144-1151
73. Tokmak F., Quack I., Schieren G., et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23 (2008) 4016-4020
74. Chandra P., Binongo J.N., Ziegler T.R., et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 14 (2008) 10-17
75. Chonchol M., and Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 71 (2007) 134-139
76. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117 (2008) 503-511
77. Martins D., Wolf M., Pan D., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167 (2007) 1159-1165
78. Hermann M., and Ruschitzka F. Vitamin D and hypertension. Curr Hypertens Rep 10 (2008) 49-51
79. de Boer I.H., Ioannou G.N., Kestenbaum B., Brunzell J.D., and Weiss N.S. 25-hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 50 (2007) 69-77
80. Kautzky-Willer A., Pacini G., Barnas U., et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 47 (1995) 200-206
81. Perez-Castrillon J.L., Vega G., Abad L., et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99 (2007) 903-905
82. Mizobuchi M., Morrissey J., Finch J.L., et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18 (2007) 1796-1806
83. Leon F., Kazim H., Masahide M., Jane F., and Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorated cardiac oxidative injury in uremic rats. Paper presented at: American Society of Nephrology Annual Meeting; (2007) Nov 2-5; San Francisco, CA
84. Pei Y.P., Greenwood C.M., Chery A.L., and Wu G.G. Racial differences in survival of patients on dialysis. Kidney Int 58 (2000) 1293-1299
85. Gutierrez O., Isakova T., Andress D.L., Levin A., and Wolf M. Racial differences in the prevalence and severity of disordered mineral metabolism in chronic kidney disease. Paper presented at: American Society of Nephrology Annual Meeting; (2007) Nov 2-5; San Francisco, CA
86. Wolf M., Betancourt J., Chang Y., et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 19 (2008) 1379-1388
87. Wolf M. Active vitamin D and survival. J Am Soc Nephrol 19 (2008) 1442-1443